肢端黑色素瘤的诊断和治疗进展

Ahmad ALHASKAWI; Sohaib Hasan Abdullah EZZI; 董延钊; 周海英; 王泽伟; 来经天; 姚成俊; Vishnu Goutham KOTA; Mohamed Hasan Abdulla Hasan ABDULLA; 卢荟

doi:10.1631/jzus.B2300221

Your Location：

Home >

Browse articles >

肢端黑色素瘤的诊断和治疗进展

Scan for full text

文章被引用时，请邮件提醒。

Submit

Review | Updated：2024-02-01

肢端黑色素瘤的诊断和治疗进展
Recent advancements in the diagnosis and treatment of acral melanoma
浙江大学学报（英文版）（B辑：生物医学和生物技术） 2024年25卷第2期页码：106-122
Affiliations：

1.Department of Orthopedics, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China
2.Department of Orthopaedics, Third Xiangya Hospital, Central South University, Changsha 410013, China
3.Zhejiang University School of Medicine, Hangzhou 310058, China
4.Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Zhejiang University, Hangzhou 310058, China
Funds：

the Zhejiang Provincial Natural Science Foundation of China(LS21H060001);the Alibaba Youth Studio Project(ZJU-032);the Zhejiang Province Medical and Health Science and Technology Program(2022KY1455;2022RC136)
DOI：10.1631/jzus.B2300221
中图分类号：
CSTR：

Ahmad ALHASKAWI,Sohaib Hasan Abdullah EZZI,董延钊等.肢端黑色素瘤的诊断和治疗进展[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2024,25(02):106-122.

Ahmad ALHASKAWI, Sohaib Hasan Abdullah EZZI, Yanzhao DONG, et al. Recent advancements in the diagnosis and treatment of acral melanoma[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2024,25(2):106-122.
Ahmad ALHASKAWI,Sohaib Hasan Abdullah EZZI,董延钊等.肢端黑色素瘤的诊断和治疗进展[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2024,25(02):106-122. DOI： 10.1631/jzus.B2300221.

Ahmad ALHASKAWI, Sohaib Hasan Abdullah EZZI, Yanzhao DONG, et al. Recent advancements in the diagnosis and treatment of acral melanoma[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2024,25(2):106-122. DOI： 10.1631/jzus.B2300221.

摘要

肢端黑色素瘤（AM）是深色皮肤患者中最常见的黑色素瘤组织学亚型，常伴有更差的预后和高死亡率，主要原因为早期病变的不典型特征导致诊断延误。由于AM的临床和组织病理学特征与其他形式的皮肤黑色素瘤相近，其早期检测需要综合各种诊断模式的多学科方法，包括临床检查、皮肤镜检查、组织病理学检查、分子检测、放射学成像和血液检测。虽然手术是AM的首选治疗方法，但是根据疾病的分期和潜在病因，也可以采用其他治疗方案。免疫检查点抑制剂、分子靶向治疗、放疗、化疗和溶瘤病毒治疗在AM治疗上具有应用前景。在本文中，我们概述了AM诊断和治疗方法的最新进展，强调了早期发现和及时、个性化管理在这一具有挑战性疾病诊疗上的重要性。

Abstract

Acral melanoma (AM) is the most common histologic subtype of melanoma in dark-skinned patients and is associated with a worse prognosis and a high mortality rate, largely due to the inconspicuous nature of early-stage lesions, which can lead to late diagnosis. Because of the overlapping clinical and histopathological features of AM with other forms of cutaneous melanomas, early detection of AM requires a multidisciplinary approach that integrates various diagnostic modalities, including clinical examination, dermoscopy, histopathology, molecular testing, radiological imaging, and blood tests. While surgery is the preferred method of treatment for AM, other therapeutic options may be employed based on the stage and underlying etiology of the disease. Immune checkpoint inhibitors, molecular targeted therapy, radiotherapy, chemotherapy, and oncolytic virotherapy represent promising advanced treatment options for AM. In this review, we provide an overview of the latest advancements in diagnostic and therapeutic methods for AM, highlighting the importance of early detection and the prompt, individualized management of this challenging disease.

关键词

肢端黑色素瘤肢端雀斑样黑色素瘤肢端痣皮肤恶性黑色素瘤皮肤镜检查溶瘤病毒治疗

Keywords

Acral melanomaAcral lentiginous melanomaAcral nevusCutaneous malignant melanomaDermoscopyOncolytic virotherapy

references

Abbasi NR, Shaw HM, Rigel DS, et al., 2004. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA, 292(22):2771-2776. https://doi.org/10.1001/jama.292.22.2771https://doi.org/10.1001/jama.292.22.2771

Alemany R, 2013. Viruses in cancer treatment. Clin Transl Oncol, 15(3):182-188. https://doi.org/10.1007/s12094-012-0951-7https://doi.org/10.1007/s12094-012-0951-7

Andtbacka RHI, Kaufman HL, Collichio F, et al., 2015. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol, 33(25):2780-2788. https://doi.org/10.1200/jco.2014.58.3377https://doi.org/10.1200/jco.2014.58.3377

Arasanz H, Gato-Cañas M, Zuazo M, et al., 2017. PD1 signal transduction pathways in T cells. Oncotarget, 8(31):51936-51945. https://doi.org/10.18632/oncotarget.17232https://doi.org/10.18632/oncotarget.17232

Arrington JH III, Reed RJ, Ichinose H, et al., 1977. Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. Am J Surg Pathol, 1(2):131-143.

Ascierto PA, Schadendorf D, Berking C, et al., 2013. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol, 14(3):249-256. https://doi.org/10.1016/s1470-2045(13)70024-xhttps://doi.org/10.1016/s1470-2045(13)70024-x

Bastian BC, 2014. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol: Mech Dis, 9:239-271. https://doi.org/10.1146/annurev-pathol-012513-104658https://doi.org/10.1146/annurev-pathol-012513-104658

Beadling C, Jacobson-Dunlop E, Hodi FS, et al., 2008. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res, 14(21):6821-6828. https://doi.org/10.1158/1078-0432.Ccr-08-0575https://doi.org/10.1158/1078-0432.Ccr-08-0575

Beasley GM, Caudle A, Petersen RP, et al., 2009. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg, 208(5):706-715. https://doi.org/10.1016/j.jamcollsurg.2008.12.019https://doi.org/10.1016/j.jamcollsurg.2008.12.019

Bello DM, Chou JF, Panageas KS, et al., 2013. Prognosis of acral melanoma: a series of 281 patients. Ann Surg Oncol, 20(11):3618-3625. https://doi.org/10.1245/s10434-013-3089-0https://doi.org/10.1245/s10434-013-3089-0

Bian SX, Hwang L, Hwang J, et al., 2021. Acral lentiginous melanoma—population, treatment, and survival using the NCDB from 2004 to 2015. Pigment Cell Melanoma Res, 34(6):1049-1061. https://doi.org/10.1111/pcmr.12999https://doi.org/10.1111/pcmr.12999

Bichakjian CK, Halpern AC, Johnson TM, et al., 2011. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol, 65(5):1032-1047. https://doi.org/10.1016/j.jaad.2011.04.031https://doi.org/10.1016/j.jaad.2011.04.031

Boyd AS, Rapini RP, 1994. Acral melanocytic neoplasms: a histologic analysis of 158 lesions. J Am Acad Dermatol, 31(5 Pt 1):740-745. https://doi.org/10.1016/s0190-9622(94)70235-7https://doi.org/10.1016/s0190-9622(94)70235-7

Bradford PT, Goldstein AM, McMaster ML, et al., 2009. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986‒2005. Arch Dermatol, 145(4):427-434. https://doi.org/10.1001/archdermatol.2008.609https://doi.org/10.1001/archdermatol.2008.609

Bravo Puccio F, Chian C, 2011. Acral junctional nevus versus acral lentiginous melanoma in situ: a differential diagnosis that should be based on clinicopathologic correlation. Arch Pathol Lab Med, 135(7):847-852. https://doi.org/10.5858/2010-0323-rar.1https://doi.org/10.5858/2010-0323-rar.1

Bristow IR, de Berker DAR, 2010. Development of a practical guide for the early recognition for malignant melanoma of the foot and nail unit. J Foot Ankle Res, 3:22. https://doi.org/10.1186/1757-1146-3-22https://doi.org/10.1186/1757-1146-3-22

Cabrera R, Recule F, 2018. Unusual clinical presentations of malignant melanoma: a review of clinical and histologic features with special emphasis on dermatoscopic findings. Am J Clin Dermatol, 19(S1):15-23. https://doi.org/10.1007/s40257-018-0373-6https://doi.org/10.1007/s40257-018-0373-6

Cascinelli N, Zurrida S, Galimberti V, et al., 1994. Acral lentiginous melanoma. A histological type without prognostic significance. J Dermatol Surg Oncol, 20(12):817-822. https://doi.org/10.1111/j.1524-4725.1994.tb03711.xhttps://doi.org/10.1111/j.1524-4725.1994.tb03711.x

Castaneda CA, Torres-Cabala C, Castillo M, et al., 2017. Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. Clin Transl Oncol, 19(12):1478-1488. https://doi.org/10.1007/s12094-017-1685-3https://doi.org/10.1007/s12094-017-1685-3

Chang AE, Karnell LH, Menck HR, 1998. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer, 83(8):1664-1678. https://doi.org/10.1002/(sici)1097-0142(19981015)83:‍8<1664::aid-cncr23>3.0.co;2-ghttps://doi.org/10.1002/(sici)1097-0142(19981015)83:‍8<1664::aid-cncr23>3.0.co;2-g

Chapman PB, Robert C, Larkin J, et al., 2017. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol, 28(10):2581-2587. https://doi.org/10.1093/annonc/mdx339https://doi.org/10.1093/annonc/mdx339

Chesney J, Puzanov I, Collichio F, et al., 2018. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol, 36(17):1658-1667. https://doi.org/10.1200/jco.2017.73.7379https://doi.org/10.1200/jco.2017.73.7379

Chuah SY, Tsilika K, Chiaverini C, et al., 2015. Dermoscopic features of congenital acral melanocytic naevi in children: a prospective comparative and follow-up study. Br J Dermatol, 172(1):88-93. https://doi.org/10.1111/bjd.13187https://doi.org/10.1111/bjd.13187

Cinotti E, Debarbieux S, Perrot JL, et al., 2016. Reflectance confocal microscopy features of acral lentiginous melanoma: a comparative study with acral nevi. J Eur Acad Dermatol Venereol, 30(7):1125-1128. https://doi.org/10.1111/jdv.13399https://doi.org/10.1111/jdv.13399

Coit DG, Thompson JA, Algazi A, et al., 2016a. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 14(4):450-473. https://doi.org/10.6004/jnccn.2016.0051https://doi.org/10.6004/jnccn.2016.0051

Coit DG, Thompson JA, Algazi A, et al., 2016b. NCCN guidelines insights: melanoma, version 3.2016. J Natl Compr Canc Netw, 14(8):945-958. https://doi.org/10.6004/jnccn.2016.0101https://doi.org/10.6004/jnccn.2016.0101

Coit DG, Thompson JA, Albertini MR, et al., 2019. Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 17(4):367-402. https://doi.org/10.6004/jnccn.2019.0018https://doi.org/10.6004/jnccn.2019.0018

Costello CM, Ghanavatian S, Temkit M, et al., 2018. Educational and practice gaps in the management of volar melanocytic lesions. J Eur Acad Dermatol Venereol, 32(9):1450-1455. https://doi.org/10.1111/jdv.14712https://doi.org/10.1111/jdv.14712

Curtin JA, Fridlyand J, Kageshita T, et al., 2005. Distinct sets of genetic alterations in melanoma. N Engl J Med, 353(20):2135-2147. https://doi.org/10.1056/NEJMoa050092https://doi.org/10.1056/NEJMoa050092

Curtin JA, Busam K, Pinkel D, et al., 2006. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol, 24(26):4340-4346. https://doi.org/10.1200/jco.2006.06.2984https://doi.org/10.1200/jco.2006.06.2984

Darmawan CC, Jo G, Montenegro SE, et al., 2019. Early detection of acral melanoma: a review of clinical, dermoscopic, histopathologic, and molecular characteristics. J Am Acad Dermatol, 81(3):805-812. https://doi.org/10.1016/j.jaad.2019.01.081https://doi.org/10.1016/j.jaad.2019.01.081

De Facto, Eng.LSM.lv, 2019. Rigvir cancer treatment at center of fresh controversy. https://eng.lsm.lvhttps://eng.lsm.lv

de Lima Vazquez V, Vicente AL, Carloni A, et al., 2016. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. Melanoma Res, 26(2):93-99. https://doi.org/10.1097/cmr.0000000000000222https://doi.org/10.1097/cmr.0000000000000222

Diaz A, Puig-Butillé JA, Valera A, et al., 2014. TERT and AURKA gene copy number gains enhance the detection of acral lentiginous melanomas by fluorescence in situ hybridization. J Mol Diagn, 16(2):198-206. https://doi.org/10.1016/j.jmoldx.2013.10.009https://doi.org/10.1016/j.jmoldx.2013.10.009

Dobson R, Burgess MI, Valle JW, et al., 2014. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. Br J Cancer, 111(9):1703-1709. https://doi.org/10.1038/bjc.2014.468https://doi.org/10.1038/bjc.2014.468

Doniņa S, Strēle I, Proboka G, et al., 2015. Adapted ECHO-7 virus rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res, 25(5):421-426. https://doi.org/10.1097/cmr.0000000000000180https://doi.org/10.1097/cmr.0000000000000180

Eggermont AMM, Blank CU, Mandala M, et al., 2018. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med, 378(19):1789-1801. https://doi.org/10.1056/NEJMoa1802357https://doi.org/10.1056/NEJMoa1802357

Espada J, Calvo MB, Díaz-Prado S, et al., 2009. Wnt signalling and cancer stem cells. Clin Transl Oncol, 11(7):411-427. https://doi.org/10.1007/s12094-009-0380-4https://doi.org/10.1007/s12094-009-0380-4

Fan Q, Cohen S, John B, et al., 2015. Melanoma in situ treated with topical imiquimod for management of persistently positive margins: a review of treatment methods. Ochsner J, 15(4):443-447.

Faries MB, Thompson JF, Cochran AJ, et al., 2017. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med, 376(23):2211-2222. https://doi.org/10.1056/NEJMoa1613210https://doi.org/10.1056/NEJMoa1613210

Farrow NE, Leddy M, Landa K, et al., 2020. Injectable therapies for regional melanoma. Surg Oncol Clin N Am, 29(3):433-444. https://doi.org/10.1016/j.soc.2020.02.008https://doi.org/10.1016/j.soc.2020.02.008

Felton S, Taylor RS, Srivastava D, 2016. Excision margins for melanoma in situ on the head and neck. Dermatol Surg, 42(3):327-334. https://doi.org/10.1097/dss.0000000000000648https://doi.org/10.1097/dss.0000000000000648

Fernandez-Flores A, Cassarino DS, 2017. Histopathological diagnosis of acral lentiginous melanoma in early stages. Ann Diagn Pathol, 26:64-69. https://doi.org/10.1016/j.anndiagpath.2016.08.005https://doi.org/10.1016/j.anndiagpath.2016.08.005

Flaherty KT, Robert C, Hersey P, et al., 2012. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med, 367(2):107-114. https://doi.org/10.1056/NEJMoa1203421https://doi.org/10.1056/NEJMoa1203421

Frew SE, Sammut SM, Shore AF, et al., 2008. Chinese health biotech and the billion-patient market. Nat Biotechnol, 26(1):37-53. https://doi.org/10.1038/nbt0108-37https://doi.org/10.1038/nbt0108-37

Friedlander P, Hodi FS, 2010. Advances in targeted therapy for melanoma. Clin Adv Hematol Oncol, 8(9):619-627.

Fukuhara H, Ino Y, Todo T, 2016. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci, 107(10):1373-1379. https://doi.org/10.1111/cas.13027https://doi.org/10.1111/cas.13027

Garbe C, Amaral T, Peris K, et al., 2020. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics ‒ Update 2019. Eur J Cancer, 126:141-158. https://doi.org/10.1016/j.ejca.2019.11.014https://doi.org/10.1016/j.ejca.2019.11.014

Gartner JJ, Davis S, Wei XM, et al., 2012. Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma. BMC Genomics, 13:505. https://doi.org/10.1186/1471-2164-13-505https://doi.org/10.1186/1471-2164-13-505

Greaves WO, Verma S, Patel KP, et al., 2013. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn, 15(2):220-226. https://doi.org/10.1016/j.jmoldx.2012.10.002https://doi.org/10.1016/j.jmoldx.2012.10.002

Gumaste PV, Fleming NH, Silva I, et al., 2014. Analysis of recurrence patterns in acral versus nonacral melanoma: should histologic subtype influence treatment guidelines? J Natl Compr Canc Netw, 12(12):1706-1712. https://doi.org/10.6004/jnccn.2014.0172https://doi.org/10.6004/jnccn.2014.0172

Häfliger EM, Ramelyte E, Mangana J, et al., 2018. Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis. Melanoma Res, 28(5):442-450. https://doi.org/10.1097/cmr.0000000000000465https://doi.org/10.1097/cmr.0000000000000465

Hamid O, Puzanov I, Dummer R, et al., 2017. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer, 86:37-45. https://doi.org/10.1016/j.ejca.2017.07.022https://doi.org/10.1016/j.ejca.2017.07.022

Han B, Hur K, Ohn J, et al., 2020. Acral lentiginous melanoma in situ: dermoscopic features and management strategy. Sci Rep, 10:20503. https://doi.org/10.1038/s41598-020-77425-zhttps://doi.org/10.1038/s41598-020-77425-z

Hauschild A, Grob JJ, Demidov LV, et al., 2012. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 380(9839):358-365. https://doi.org/10.1016/s0140-6736(12)60868-xhttps://doi.org/10.1016/s0140-6736(12)60868-x

Hayward NK, Wilmott JS, Waddell N, et al., 2017. Whole-genome landscapes of major melanoma subtypes. Nature, 545(7653):175-180. https://doi.org/10.1038/nature22071https://doi.org/10.1038/nature22071

Hervieu A, Rébé C, Végran F, et al., 2013. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol, 133(2):499-508. https://doi.org/10.1038/jid.2012.273https://doi.org/10.1038/jid.2012.273

Huang K, Fan J, Misra S, 2020. Acral lentiginous melanoma: incidence and survival in the United States, 2006‒2015, an analysis of the SEER registry. J Surg Res, 251:329-339. https://doi.org/10.1016/j.jss.2020.02.010https://doi.org/10.1016/j.jss.2020.02.010

Ide T, Ito T, Wada-Ohno M, et al., 2021. Preoperative screening CT and PET/CT scanning for acral melanoma: is it necessary? J Clin Med, 10(4):811. https://doi.org/10.3390/jcm10040811https://doi.org/10.3390/jcm10040811

Ishihara Y, Saida T, Miyazaki A, et al., 2006. Early acral melanoma in situ: correlation between the parallel ridge pattern on dermoscopy and microscopic features. Am J Dermatopathol, 28(1):21-27. https://doi.org/10.1097/01.dad.0000187931.05030.a0https://doi.org/10.1097/01.dad.0000187931.05030.a0

Ito H, Aoki H, Kühnel F, et al., 2006. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst, 98(9):625-636. https://doi.org/10.1093/jnci/djj161https://doi.org/10.1093/jnci/djj161

Ito T, Wada M, Nagae K, et al., 2015. Acral lentiginous melanoma: who benefits from sentinel lymph node biopsy? J Am Acad Dermatol, 72(1):71-77. https://doi.org/10.1016/j.jaad.2014.10.008https://doi.org/10.1016/j.jaad.2014.10.008

Kaufman HL, Kohlhapp FJ, Zloza A, 2015. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov, 14(9):642-662. https://doi.org/10.1038/nrd4663https://doi.org/10.1038/nrd4663

Kaunitz GJ, Cottrell TR, Lilo M, et al., 2017. Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Invest, 97(9):1063-1071. https://doi.org/10.1038/labinvest.2017.64https://doi.org/10.1038/labinvest.2017.64

Khayat D, Rixe O, Martin G, et al., 2003. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer, 97(8):1941-1946. https://doi.org/10.1002/cncr.11272https://doi.org/10.1002/cncr.11272

Kilinc Karaarslan I, Akalin T, Unal I, et al., 2007. Atypical melanosis of the foot showing a dermoscopic feature of the parallel ridge pattern. J Dermatol, 34(1):56-59. https://doi.org/10.1111/j.1346-8138.2007.00217.xhttps://doi.org/10.1111/j.1346-8138.2007.00217.x

Kim JY, Hwang EJ, Choi M, et al., 2014. Recurrent acral lentiginous melanoma in situ suggesting the field cell theory. Ann Dermatol, 26(6):779-781. https://doi.org/10.5021/ad.2014.26.6.779https://doi.org/10.5021/ad.2014.26.6.779

Kim SY, Kim SN, Hahn HJ, et al., 2015. Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. J Am Acad Dermatol, 72(6):1036-1046.e2. https://doi.org/10.1016/j.jaad.2015.02.1113https://doi.org/10.1016/j.jaad.2015.02.1113

Kirkwood JM, Richards T, Zarour HM, et al., 2002. Immunomodulatory effects of high-dose and low-dose interferon α2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer, 95(5):1101-1112. https://doi.org/10.1002/cncr.10775https://doi.org/10.1002/cncr.10775

Kong LQ, Tan KP, Tan HW, et al., 2020. Use of magnetic resonance imaging as a noninvasive technique to identify acral lentiginous melanoma. J Am Acad Dermatol, 83(2):e121-e123. https://doi.org/10.1016/j.jaad.2019.09.025https://doi.org/10.1016/j.jaad.2019.09.025

Koski A, Kangasniemi L, Escutenaire S, et al., 2010. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther, 18(10):1874-1884. https://doi.org/10.1038/mt.2010.161https://doi.org/10.1038/mt.2010.161

Kraus SL, Haenssle HA, 2013. Early detection of cutaneous melanoma by sequential digital dermatoscopy (SDD). J Dtsch Dermatol Ges, 11(6):509-512. https://doi.org/10.1111/ddg.12072https://doi.org/10.1111/ddg.12072

Kunishige JH, Brodland DG, Zitelli JA, 2012. Surgical margins for melanoma in situ. J Am Acad Dermatol, 66(3):438-444. https://doi.org/10.1016/j.jaad.2011.06.019https://doi.org/10.1016/j.jaad.2011.06.019

Kuruppu D, Tanabe KK, 2005. Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol Ther, 4(5):524-531. https://doi.org/10.4161/cbt.4.5.1820https://doi.org/10.4161/cbt.4.5.1820

Kwon MR, Choi SH, Jang KT, et al., 2019. Acral malignant melanoma; emphasis on the primary metastasis and the usefulness of preoperative ultrasound for sentinel lymph node metastasis. Sci Rep, 9:15894. https://doi.org/10.1038/s41598-019-52180-yhttps://doi.org/10.1038/s41598-019-52180-y

Lallas A, Kyrgidis A, Koga H, et al., 2015. The BRAAFF checklist: a new dermoscopic algorithm for diagnosing acral melanoma. Br J Dermatol, 173(4):1041-1049. https://doi.org/10.1111/bjd.14045https://doi.org/10.1111/bjd.14045

LeBoit PE, 2000. A diagnosis for maniacs. Am J Dermatopathol, 22(6):556-558. https://doi.org/10.1097/00000372-200012000-00012https://doi.org/10.1097/00000372-200012000-00012

Lee JH, Choi JW, Kim YS, 2011. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol, 164(4):776-784. https://doi.org/10.1111/j.1365-2133.2010.10185.xhttps://doi.org/10.1111/j.1365-2133.2010.10185.x

Lee KT, Kim EJ, Lee DY, et al., 2016. Surgical excision margin for primary acral melanoma. J Surg Oncol, 114(8):933-939. https://doi.org/10.1002/jso.24442https://doi.org/10.1002/jso.24442

Liang WS, Hendricks W, Kiefer J, et al., 2017. Integrated gen

omic analyses reveal frequent TERT aberrations in acral melanoma. Genome Res, 27(4):524-532. https://doi.org/10.1101/gr.213348.116https://doi.org/10.1101/gr.213348.116

Lichty BD, Breitbach CJ, Stojdl DF, et al., 2014. Going viral with cancer immunotherapy. Nat Rev Cancer, 14(8):559-567. https://doi.org/10.1038/nrc3770https://doi.org/10.1038/nrc3770

Linsley PS, Bradshaw J, Greene J, et al., 1996. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity, 4(6):535-543. https://doi.org/10.1016/s1074-7613(00)80480-xhttps://doi.org/10.1016/s1074-7613(00)80480-x

Liu XY, Fang H, Chen HC, et al., 2012. An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS ONE, 7(6):e38659. https://doi.org/10.1371/journal.pone.0038659https://doi.org/10.1371/journal.pone.0038659

Llanos S, Danilla S, Barraza C, et al., 2006. Effectiveness of negative pressure closure in the integration of split thickness skin grafts: a randomized, double-masked, controlled trial. Ann Surg, 244(5):700-705. https://doi.org/10.1097/01.sla.0000217745.56657.e5https://doi.org/10.1097/01.sla.0000217745.56657.e5

Long GV, Hauschild A, Santinami M, et al., 2017a. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med, 377(19):1813-1823. https://doi.org/10.1056/NEJMoa1708539https://doi.org/10.1056/NEJMoa1708539

Long GV, Flaherty KT, Stroyakovskiy D, et al., 2017b. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol, 28(7):1631-1639. https://doi.org/10.1093/annonc/mdx176https://doi.org/10.1093/annonc/mdx176

Loosemore MP, Morales-Burgos A, Goldberg LH, 2013. Acral lentiginous melanoma of the toe treated using Mohs surgery with sparing of the digit and subsequent reconstruction using split-thickness skin graft. Dermatol Surg, 39(1 Pt 1):136-138. https://doi.org/10.1111/j.1524-4725.2012.02569.xhttps://doi.org/10.1111/j.1524-4725.2012.02569.x

Maldonado JL, Fridlyand J, Patel H, et al., 2003. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst, 95(24):1878-1890. https://doi.org/10.1093/jnci/djg123https://doi.org/10.1093/jnci/djg123

Manzano JL, Layos L, Bugés C, et al., 2016. Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med, 4(12):237. https://doi.org/10.21037/atm.2016.06.07https://doi.org/10.21037/atm.2016.06.07

Marek AJ, Ming ME, Bartlett EK, et al., 2016. Acral lentiginous histologic subtype and sentinel lymph node positivity in thin melanoma. JAMA Dermatol, 152(7):836-837. https://doi.org/10.1001/jamadermatol.2016.0875https://doi.org/10.1001/jamadermatol.2016.0875

Menis D, Maroñas-Jiménez L, Rodríguez-Peralto J, et al., 2015. Two Spanish cases of atypical melanosis of the foot, an early stage of acral lentiginous melanoma in situ. Br J Dermatol, 172(5):1436-1438. https://doi.org/10.1111/bjd.13485https://doi.org/10.1111/bjd.13485

Miller DM, Flaherty KT, Tsao H, 2014. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Semin Cutan Med Surg, 33(2):60-67. https://doi.org/10.12788/j.sder.0081https://doi.org/10.12788/j.sder.0081

Mun JH, Jo G, Darmawan CC, et al., 2018. Association between Breslow thickness and dermoscopic findings in acral melanoma. J Am Acad Dermatol, 79(5):831-835. https://doi.org/10.1016/j.jaad.2018.06.004https://doi.org/10.1016/j.jaad.2018.06.004

Nakamura Y, Fujisawa Y, 2018. Diagnosis and management of acral lentiginous melanoma. Curr Treat Options Oncol, 19(8):42. https://doi.org/10.1007/s11864-018-0560-yhttps://doi.org/10.1007/s11864-018-0560-y

Nakamura Y, Fujisawa Y, Okiyama N, et al., 2018. Surgical damage to the lymphatic system promotes tumor growth via impaired adaptive immune response. J Dermatol Sci, 90(1):46-51. https://doi.org/10.1016/j.jdermsci.2017.12.016https://doi.org/10.1016/j.jdermsci.2017.12.016

Ocampo-Garza J, di Chiacchio NG, Haneke E, et al., 2017. Subungual melanoma in situ treated with imiquimod 5% cream after conservative surgery recurrence. J Drugs Dermatol, 16(3):268-270.

Ogata D, Arai E, Goto Y, et al., 2018. Pilot study on the correlation between dermoscopic patterns and fluorescence in situ hybridization findings using whole-slide digital imaging for acral volar melanocytic lesions. J Dermatol, 45(7):830-836. https://doi.org/10.1111/1346-8138.14324https://doi.org/10.1111/1346-8138.14324

Oh BH, Lee SH, Nam KA, et al., 2013. Comparison of negative pressure wound therapy and secondary intention healing after excision of acral lentiginous melanoma on the foot. Br J Dermatol, 168(2):333-338. https://doi.org/10.1111/bjd.12099https://doi.org/10.1111/bjd.12099

Oh TS, Bae EJ, Ro KW, et al., 2011. Acral lentiginous melanoma developing during long-standing atypical melanosis: usefulness of dermoscopy for detection of early acral melanoma. Ann Dermatol, 23(3):400-404. https://doi.org/10.5021/ad.2011.23.3.400https://doi.org/10.5021/ad.2011.23.3.400

Omholt K, Grafström E, Kanter-Lewensohn L, et al., 2011. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res, 17(12):3933-3942. https://doi.org/10.1158/1078-0432.Ccr-10-2917https://doi.org/10.1158/1078-0432.Ccr-10-2917

Orgaz JL, Sanz-Moreno V, 2013. Emerging molecular targets in melanoma invasion and metastasis. Pigment Cell Melanoma Res, 26(1):39-57. https://doi.org/10.1111/pcmr.12041https://doi.org/10.1111/pcmr.12041

Palmer SR, Erickson LA, Ichetovkin I, et al., 2011. Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc, 86(10):981-990. https://doi.org/10.4065/mcp.2011.0287https://doi.org/10.4065/mcp.2011.0287

Park HS, Cho KH, 2010. Acral lentiginous melanoma in situ: a diagnostic and management challenge. Cancers, 2(2):642-652. https://doi.org/10.3390/cancers2020642https://doi.org/10.3390/cancers2020642

Perone JA, Farrow N, Tyler DS, et al., 2018. Contemporary approaches to in-transit melanoma. J Oncol Pract, 14(5):292-300. https://doi.org/10.1200/jop.18.00063https://doi.org/10.1200/jop.18.00063

Phan A, Dalle S, Touzet S, et al., 2010. Dermoscopic features of acral lentiginous melanoma in a large series of 110 cases in a white population. Br J Dermatol, 162(4):765-771. https://doi.org/10.1111/j.1365-2133.2009.09594.xhttps://doi.org/10.1111/j.1365-2133.2009.09594.x

Pol J, Kroemer G, Galluzzi L, 2016. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology, 5(1):e1115641. https://doi.org/10.1080/2162402x.2015.1115641https://doi.org/10.1080/2162402x.2015.1115641

Rafique I, Kirkwood JM, Tarhini AA, 2015. Immune checkpoint blockade and interferon-α in melanoma. Semin Oncol, 42(3):436-447. https://doi.org/10.1053/j.seminoncol.2015.02.012https://doi.org/10.1053/j.seminoncol.2015.02.012

Rajabi-Estarabadi A, Bittar JM, Zheng CW, et al., 2019. Optical coherence tomography imaging of melanoma skin cancer. Lasers Med Sci, 34(2):411-420. https://doi.org/10.1007/s10103-018-2696-1https://doi.org/10.1007/s10103-018-2696-1

Ravaioli GM, Dika E, Lambertini M, et al., 2019. Acral melanoma: correlating the clinical presentation to the mutational status. G Ital Dermatol Venereol, 154(5):567-572. https://doi.org/10.23736/s0392-0488.18.05791-7https://doi.org/10.23736/s0392-0488.18.05791-7

Ribas A, Dummer R, Puzanov I, et al., 2017. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell, 170(6):1109-1119.e10. https://doi.org/10.1016/j.cell.2017.08.027https://doi.org/10.1016/j.cell.2017.08.027

Ridgeway CA, Hieken TJ, Ronan SG, et al., 1995. Acral lentigin

ous melanoma. Arch Surg, 130(1):88-92. https://doi.org/10.1001/archsurg.1995.01430010090019https://doi.org/10.1001/archsurg.1995.01430010090019

Robert C, Thomas L, Bondarenko I, et al., 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med, 364(26):2517-2526. https://doi.org/10.1056/NEJMoa1104621https://doi.org/10.1056/NEJMoa1104621

Robert C, Long GV, Brady B, et al., 2015. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med, 372(4):320-330. https://doi.org/10.1056/NEJMoa1412082https://doi.org/10.1056/NEJMoa1412082

Robinson C, Xu MM, Nair SK, et al., 2022. Oncolytic viruses in melanoma. Front Biosci, 27(2):63. https://doi.org/10.31083/j.fbl2702063https://doi.org/10.31083/j.fbl2702063

Russo I, Zorzetto L, Frigo AC, et al., 2017. A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience. Eur J Dermatol, 27(5):482-486. https://doi.org/10.1684/ejd.2017.3069https://doi.org/10.1684/ejd.2017.3069

Saida T, 1989. Malignant melanoma in situ on the sole of the foot. Its clinical and histopathologic characteristics. Am J Dermatopathol, 11(2):124-130. https://doi.org/10.1097/00000372-198911020-00003https://doi.org/10.1097/00000372-198911020-00003

Saida T, Koga H, 2007. Dermoscopic patterns of acral melanocytic nevi: their variations, changes, and significance. Arch Dermatol, 143(11):1423-1426. https://doi.org/10.1001/archderm.143.11.1423https://doi.org/10.1001/archderm.143.11.1423

Saida T, Koga H, Uhara H, 2011. Key points in dermoscopic differentiation between early acral melanoma and acral nevus. J Dermatol, 38(1):25-34. https://doi.org/10.1111/j.1346-8138.2010.01174.xhttps://doi.org/10.1111/j.1346-8138.2010.01174.x

Sanki A, Uren RF, Moncrieff M, et al., 2009. Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. J Clin Oncol, 27(33):5614-5619. https://doi.org/10.1200/jco.2008.21.4882https://doi.org/10.1200/jco.2008.21.4882

Savarese I, Papi F, D'Errico A, et al., 2015. Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells. Clin Exp Dermatol, 40(1):27-30. https://doi.org/10.1111/ced.12469https://doi.org/10.1111/ced.12469

Scolyer RA, Thompson JF, McCarthy SW, et al., 2006. Letters to the editor. Australas J Dermatol, 47(1):71-73. https://doi.org/10.1111/j.1440-0960.2006.00230.xhttps://doi.org/10.1111/j.1440-0960.2006.00230.x

Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, et al., 1999. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys, 44(3):607-618. https://doi.org/10.1016/s0360-3016(99)00066-8https://doi.org/10.1016/s0360-3016(99)00066-8

Senzer NN, Kaufman HL, Amatruda T, et al., 2009. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol, 27(34):5763-5771. https://doi.org/10.1200/jco.2009.24.3675https://doi.org/10.1200/jco.2009.24.3675

Seo J, Oh Y, Kim SK, et al., 2021. Slow Mohs micrographic surgery for acral melanoma treatment in Korean patients. Dermatol Surg, 47(2):e42-e46. https://doi.org/10.1097/DSS.0000000000002827https://doi.org/10.1097/DSS.0000000000002827

Sharpe AH, Wherry EJ, Ahmed R, et al., 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol, 8(3):239-245. https://doi.org/10.1038/ni1443https://doi.org/10.1038/ni1443

Signoretti S, Annessi G, Puddu P, et al., 1999. Melanocytic nevi of palms and soles: a histological study according to the plane of section. Am J Surg Pathol, 23(3):283-287. https://doi.org/10.1097/00000478-199903000-00006https://doi.org/10.1097/00000478-199903000-00006

Su J, Yu WJ, Liu JY, et al., 2017. Fluorescence in situ hybridisation as an ancillary tool in the diagnosis of acral melanoma: a review of 44 cases. Pathology, 49(7):740-749. https://doi.org/10.1016/j.pathol.2017.08.006https://doi.org/10.1016/j.pathol.2017.08.006

Swetter SM, Tsao H, Bichakjian CK, et al., 2019. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol, 80(1):208-250. https://doi.org/10.1016/j.jaad.2018.08.055https://doi.org/10.1016/j.jaad.2018.08.055

Swetter SM, Thompson JA, Albertini MR, et al., 2021. NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021. J Natl Compr Canc Netw, 19(4):364-376. https://doi.org/10.6004/jnccn.2021.0018https://doi.org/10.6004/jnccn.2021.0018

Takahashi Y, Nishikawa M, Suehara T, et al., 2008. Gene silencing of β-catenin in melanoma cells retards their growth but promotes the formation of pulmonary metastasis in mice. Int J Cancer, 123(10):2315-2320. https://doi.org/10.1002/ijc.23812https://doi.org/10.1002/ijc.23812

Tanioka M, 2011. Benign acral lesions showing parallel ridge pattern on dermoscopy. J Dermatol, 38(1):41-44. https://doi.org/10.1111/j.1346-8138.2010.01128.xhttps://doi.org/10.1111/j.1346-8138.2010.01128.x

Teramoto Y, Keim U, Gesierich A, et al., 2018. Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. Br J Dermatol, 178(2):443-451. https://doi.org/10.1111/bjd.15803https://doi.org/10.1111/bjd.15803

Tod BM, Schneider JW, Bowcock AM, et al., 2020. The tumor genetics of acral melanoma: what should a dermatologist know? JAAD Int, 1(2):135-147. https://doi.org/10.1016/j.jdin.2020.07.004https://doi.org/10.1016/j.jdin.2020.07.004

Viros A, Fridlyand J, Bauer J, et al., 2008. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med, 5(6):e120. https://doi.org/10.1371/journal.pmed.0050120https://doi.org/10.1371/journal.pmed.0050120

Wada M, Ito T, Tsuji G, et al., 2017. Acral lentiginous melanoma versus other melanoma: a single-center analysis in Japan. J Dermatol, 44(8):932-938. https://doi.org/10.1111/1346-8138.13834https://doi.org/10.1111/1346-8138.13834

Wang WJ, Edington HD, Rao UNM, et al., 2007. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNαb. Clin Cancer Res, 13(5):1523-1531. https://doi.org/10.1158/1078-0432.Ccr-06-1387https://doi.org/10.1158/1078-0432.Ccr-06-1387

Weyers W, Euler M, Diaz-Cascajo C, et al., 1999. Classification of cutaneous malignant melanoma: a reassessment of histopathologic criteria for the distinction of different types. Cancer, 86(2):288-299. https://doi.org/10.1002/(sici)1097-0142(19990715)86:2<288::aid-cncr13>3.0.co;2-shttps://doi.org/10.1002/(sici)1097-0142(19990715)86:2<288::aid-cncr13>3.0.co;2-s

Wollmann G, Davis JN, Bosenberg MW, et al., 2013. Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes. J Virol, 87(12):6644-6659. https://doi.org/10.1128/jvi.03311-12https://doi.org/10.1128/jvi.03311-12

Woodman SE, Davies MA, 2010. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol, 80(5):568-574. https://doi.org/10.1016/j.bcp.2010.04.032https://doi.org/10.1016/j.bcp.2010.04.032

Wu XC, Eide MJ, King J, et al., 2011. Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999‒2006. J Am Acad Dermatol, 65(5 Suppl 1):S26.e1-S37.e13. https://doi.org/10.1016/j.jaad.2011.05.034https://doi.org/10.1016/j.jaad.2011.05.034

Xu SX, Yang ZZ, Zhang JY, et al., 2015. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2. DNA Cell Biol, 34(1):69-77. https://doi.org/10.1089/dna.2014.2590https://doi.org/10.1089/dna.2014.2590

Yamazaki N, Tanaka R, Tsutsumida A, et al., 2015. BRAF V600 mutations and pathological features in Japanese melanoma patients. Melanoma Res, 25(1):9-14. https://doi.org/10.1097/cmr.0000000000000091https://doi.org/10.1097/cmr.0000000000000091

Yang TT, Yu S, Ke CK, et al., 2023. The genomic landscape of melanoma and its therapeutic implications. Genes (Basel), 14(5):1021. https://doi.org/10.3390/genes14051021https://doi.org/10.3390/genes14051021

Yang ZZ, Xie L, Huang YC, et al., 2011. Clinical features of malignant melanoma of the finger and therapeutic efficacies of different treatments. Oncol Lett, 2(5):811-815. https://doi.org/10.3892/ol.2011.324https://doi.org/10.3892/ol.2011.324

Yeh I, Jorgenson E, Shen L, et al., 2019. Targeted genomic profiling of acral melanoma. J Natl Cancer Inst, 111(10):1068-1077. https://doi.org/10.1093/jnci/djz005https://doi.org/10.1093/jnci/djz005

York K, Dlova NC, Wright CY, et al., 2016. Primary cutaneous malignancies in the Northern Cape Province of South Africa: a retrospective histopathological review. S Afr Med J, 107(1):83-88. https://doi.org/10.7196/SAMJ.2016.v107.i1.10924https://doi.org/10.7196/SAMJ.2016.v107.i1.10924

Zebary A, Omholt K, Vassilaki I, et al., 2013. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. J Dermatol Sci, 72(3):284-289. https://doi.org/10.1016/j.jdermsci.2013.07.013https://doi.org/10.1016/j.jdermsci.2013.07.013

Zemelman VB, Valenzuela CY, Sazunic I, et al., 2014. Malignant melanoma in Chile: different site distribution between private and state patients. Biol Res, 47:34. https://doi.org/10.1186/0717-6287-47-34https://doi.org/10.1186/0717-6287-47-34

浏览量

Downloads

CSCD

工具集

关联资源

暂无数据